Search

Mihael H Polymeropoulos

from Potomac, MD
Age ~64
Get Report
Also known as:
Mihael Dr Polymeropoulos, Mihael D Polymeropoulos, Mihael P Polymeropoulos, Michael D Polymeropoulos, Michael H Polymeropoulos, Mahy H Polymeropoulos, Mahy D Polymeropoulos, Mihael Polymeropoulos Dr, Mihael S, Mihael Polymeropoul
Phone and address:
10627 Rivers Bend Ln, Rockville, MD 20854
(301) 299-0000
Related to:
Christos B Polymeropoulos, 37Aikaterine PolymeropoulosAndroniki D Polymeropoulos, 71Kathy PolymeropoulosMihales H Polymeropoulos, 64S H PolymeropoulosMahy V DimitriouVasilios Polymeropoulos, 35Katerina Polymeropoulos
Connected to:
Dean F Polymeros, 61Amos Polynice, 49Beverly Polyniak, 77Hudson Polynice, 52Martine Polynice, 33Melia A Polynice, 43Rose D Polynice, 61Ruth F Polynice, 57Tashonia Polynice, 53Dimitry V Polyntsev, 50

Mihael Polymeropoulos Phones & Addresses

  • 10627 Rivers Bend Ln, Potomac, MD 20854 (301) 299-0000 (301) 675-7761
  • 11300 Ridge Mist Ter, Potomac, MD 20854 (301) 762-6406 (301) 762-0000
  • 8301 Raymond Ln, Potomac, MD 20854 (301) 299-5381
  • 3801 Raymond Ln, Rockville, MD 20854 (301) 299-5381
  • Corolla, NC
  • Washington, DC
  • 4977 Battery Ln #420, Bethesda, MD 20814

Work

Company: VANDA PHARMACEUTICALS Address: 2200 Pennsylvania Ave Nw Suite 300E, Washington, DC 20037 Phones: (202) 296-1450 (202) 734-3417

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Psychiatry, 2007

Specialities

Neuropsychiatry (Psychiatry)

Professional Records

Medicine Doctors

Mihael Polymeropoulos Photo 1

Dr. Mihael H Polymeropoulos, Washington DC - MD (Doctor of Medicine)

View page
Specialties:
Neuropsychiatry (Psychiatry)
Address:
VANDA PHARMACEUTICALS
2200 Pennsylvania Ave Nw Suite 300E, Washington, DC 20037
(202) 296-1450 (Phone), (202) 734-3417 (Fax)
Certifications:
Psychiatry, 2007
Awards:
Healthgrades Honor Roll
Languages:
English

Business Records

Name / Title
Company / Classification
Phones & Addresses
Mihael H. Polymeropoulos
CEO, Chairman
Vanda Pharmaeuticals Inc
2200 Pennsylvania Ave NW, Washington, DC 20037
Mihael Hristos Polymeropoulos
Mihael Polymeropoulos MD
Psychiatrist
9605 Medical Ctr Dr, Rockville, MD 20850
Mihael Polymeropoulos
CEO
Vanda Pharmaceuticals
Pharmaceuticals · Mfg Pharmaceutical Preparations · Medical Development · A Development Stage Company Engaged In The Mfg of Pharmaceutical Preparations & Commercial Physical Research · Mfg Pharmaceutical Preparations & Medical Research · Mfg Pharmaceutical Preparations and Medical Research · Pharmaceutical Products-Wholes
2200 Pennsylvania Ave NW SUITE 300E, Washington, DC 20037
Washington, DC 20037
9620 Medical Ctr Dr, Rockville, MD 20850
9605 Med Ctr Dr, Rockville, MD 20850
(301) 294-9300, (240) 599-4500, (301) 294-1900

Publications

Us Patents

Methods To Predict Cholesterol Elevation During Immunosuppressant Therapy

View page
US Patent:
7732134, Jun 8, 2010
Filed:
Sep 29, 2003
Appl. No.:
10/529613
Inventors:
Sridhar Kudaravalli - Chicago IL, US
Mihael Hristos Polymeropoulos - Potomac MD, US
Rosarelis Torres - Bethesda MD, US
Curt Douglas Wolfgang - Germantown MD, US
Assignee:
Novartis AG - Basel
International Classification:
C12Q 1/68
C07H 21/04
C12P 19/34
US Classification:
435 6, 536 243, 435 912
Abstract:
This invention provides methods to predict the degree of elevation of serum cholesterol levels in patients treated with immunosuppressive medication. This invention also provides treatment strategies based on these predictions and kits to carry out these methods.

Methods Of Treating Psychosis And Schizophrenia Based On Polymorphisms In The Cntf Gene

View page
US Patent:
8460867, Jun 11, 2013
Filed:
Jun 3, 2009
Appl. No.:
12/477469
Inventors:
Sridhar Kudaravalli - Chicago IL, US
Mihael Hristos Polymeropoulos - Potomac MD, US
Assignee:
Novartis AG - Basel
International Classification:
C07H 21/04
C12Q 1/68
US Classification:
435 61, 435 611, 435 612, 435 911, 435 912, 536 231, 536 243
Abstract:
This invention relates to the use of the association between the 103 G>A polymorphism in the CNTF gene to determine antipsychotic treatment strategies in patients with psychotic disorders.

Methods For The Administration Of Iloperidone

View page
US Patent:
8586610, Nov 19, 2013
Filed:
Sep 30, 2005
Appl. No.:
11/576178
Inventors:
Curt D. Wolfgang - Germantown MD, US
Mihael H. Polymeropoulos - Potomac MD, US
Assignee:
Vanda Pharmaceuticals, Inc. - Washington DC
International Classification:
A61K 31/445
C12Q 1/68
US Classification:
514320, 435 611, 435 618
Abstract:
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.

Method And Composition For Treating A Serotonin Receptor-Mediated Condition

View page
US Patent:
8618134, Dec 31, 2013
Filed:
Dec 13, 2008
Appl. No.:
12/747912
Inventors:
Mihael H. Polymeropoulos - Potomac MD, US
Paolo Baroldi - Potomac MD, US
Curt Wolfgang - Germantown MD, US
Assignee:
Vanda Pharmaceuticals Inc. - Washington DC
International Classification:
A61K 31/445
A61K 31/41
US Classification:
514321, 514360
Abstract:
A method and composition for treating serotonin receptor-mediated conditions.

Genes Expressed In Breast Cancer As Prognostic And Therapeutic Targets

View page
US Patent:
20030064385, Apr 3, 2003
Filed:
Apr 11, 2002
Appl. No.:
10/120583
Inventors:
Marlene Dressman - Germantown MD, US
Christian Lavedan - Potomac MD, US
Mihael Polymeropoulos - Potomac MD, US
International Classification:
C12Q001/68
US Classification:
435/006000, 702/020000
Abstract:
Methods are disclosed for, determining the endocrine responsiveness of breast carcinoma and treating and monitoring the progression of breast carcinoma based on genes which are differentially expressed in breast tumors. Also disclosed are methods for identifying agents useful in the treatment of breast carcinoma, methods for monitoring the efficacy of a treatment for breast carcinoma, methods for inhibiting the proliferation of a breast carcinoma, and breast-specific vectors including the promoters of the disclosed genes.

Methods To Predict Patient Responsiveness To Tyrosine Kinase Inhibitors

View page
US Patent:
20050164196, Jul 28, 2005
Filed:
Apr 16, 2003
Appl. No.:
10/510969
Inventors:
Marlene Dressman - Germantown MD, US
Lee Mc Lean - Germantown MD, US
Mihael Polymeropoulos - Potomac MD, US
International Classification:
C12Q001/68
G06F019/00
G01N033/48
G01N033/50
US Classification:
435006000, 702020000
Abstract:
This invention relates to the use of two forms of genomic analysis to predict responsiveness of patients with tyrosine kinase responsive such as Philadelphia chromosome positive leukemia to treatment with tyrosine kinase inhibitor drugs.

Bioequivalence Determination Using Expression Profiling

View page
US Patent:
20050181516, Aug 18, 2005
Filed:
Apr 30, 2003
Appl. No.:
10/512709
Inventors:
Marlene Dressman - Germantown MD, US
Christian Lavedan - Potomac MD, US
Lee Mc Lean - Germantown MD, US
Mihael Polymeropoulos - Potomac MD, US
International Classification:
A61K038/00
A61K031/335
G05D007/00
G01N030/02
G05D011/00
G01N033/543
A61K009/22
A01N043/02
US Classification:
436161000, 424468000, 436518000, 514011000, 514449000, 700283000
Abstract:
The present invention provides methods to use expression profiles to determine the bioequivalence of two or more pharmaceutically equivalent drug formulations. In addition, this invention provides methods to select drug formulations that are able to substitute for standard drug formulations without change in clinical efficacy. In other embodiments, this invention provides computer systems, kits and databases for carrying out the methods of the invention.

Methods To Predict Ederma As A Side Effect Of Drug Treatment

View page
US Patent:
20060188878, Aug 24, 2006
Filed:
Oct 14, 2003
Appl. No.:
10/530391
Inventors:
Marlene Dressman - Germantown MD, US
Sridhar Kudaravalli - Chicago IL, US
Rachel Malinowski - Pittsburgh PA, US
Lee McLean - Medway MA, US
Mihael Polymeropoulos - Potomac MD, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
This invention provides methods to predict the likelihood of occurrence of the side effect of edema in patients treated with a drug including, but not limited to, a TKI, such as Imatinib or GLEEVEC™/GLIVEC. The methods employed use gene expression profile comparisons and the determination of specific SNPs and in the IL-1β gene. Methods of treatment of edema and kits for the performance of the above assays are also provided.
Control profile
Mihael H Polymeropoulos from Potomac, MD, age ~64 Get Report